Navigating the Complex Ion Channel Biology of TRPA1 for Pain and Respiratory Therapeutics. Access high-fidelity lentiviral vectors, species-orthogonal reagents, and selectivity panels designed for state-dependent antagonist screening.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TRPA1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TRPA1 Mutant Protein (Intracellular Domain). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View TRPA1 Products |
| Gene Delivery | TRPA1 Lentivirus Premade Particles. Full-length human TRPA1 ORF (NM_007332), HEK293 packaging. Native glycosylation. For stable cell line generation. | View TRPA1 Products |
| Stable Cell Line | TRPA1/HEK293 Stable Cell Line. Pre-constructed line for Calcium flux assays. Endotoxin <1EU/ml. Puro-resistant. | View TRPA1 Products |
| Benchmark Ab | Anti-TRPA1 Reference Antibody (Recombinant positive control). Sequence verified for expression validation. | View TRPA1 Products |
| Validator | TRPA1 siRNA Set (3 unique sequences). For knockdown verification in calcium flux and electrophysiology assays. | View TRPA1 Products |
| Selectivity Panel A | TRPV1 Recombinant Protein (Human ECD-Fc fusion, >95% purity) for counter-screening in nociception pathway. | View TRPV1 Products |
| Selectivity Panel B | TRPM8 Recombinant Protein (Human ECD-Fc fusion). For cold-sensation selectivity profiling. | View TRPM8 Products |
| Selectivity Panel C | TRPC5 Recombinant Protein (Full-length ORF lentivirus available). For calcium channel selectivity testing. | View TRPC5 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ion Channel Conformation Integrity | Full-length TRPA1 Lentivirus with native transmembrane topology preserves ankyrin repeat domain and pore loop structure for state-dependent binding studies. |
| Species Selectivity Testing (Human vs Preclinical) | Human/Mouse/Rat/Cyno ortholog lentivirus particles available with species-specific ORF cloning (Sequence Verified). |
| Off-target TRP Selectivity | Recombinant TRPV1, TRPM8, and TRPC5 proteins for comprehensive counter-screening against thermosensitive TRP family. |
| Assay Specificity Control | Chemically synthesized siRNA sets targeting distinct TRPA1 exons; validated benchmark antibody included. |
| Complex Membrane Conformation for Calcium Flux | Lentivirus-optimized cell lines for Flow Cytometry/Calcium Flux assays with native glycosylation. |
Live TRPA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The TRPA1 therapeutic landscape has undergone significant recalibration following recent Phase II discontinuations in chronic pain indications (e.g., Glenmark's GRC 17536 due to hepatotoxicity). The current strategic pivot focuses on respiratory indications (chronic cough, allergic airway inflammation) and state-dependent allosteric modulation rather than orthosteric antagonism. As the field moves toward peripheral-restricted compounds to circumvent CNS-mediated side effects, the demand for sophisticated cell-based assays capable of detecting open-channel blockade and use-dependent inhibition has intensified. Major players (Novartis, AstraZeneca, Merck) are now prioritizing chronic cough and asthma, while academic consortia explore allosteric modulators for migraine and IBD. The next wave of R&D also includes combination approaches with TRPV1 modulators.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Novartis, Merck, AstraZeneca, Eli Lilly, Glenmark, Genentech, Orion | Neuropathic Pain, Chronic Cough, Asthma, Migraine | Calcium Flux Stable Cell Lines (Need Lentivirus-expressed TRPA1 with native glycosylation) |
| Allosteric Modulator | Hydra Biosciences (Vertex), Academic Consortia | Migraine, IBD, Refractory Pain | State-Dependent Binding Assay (Need intact ankyrin repeat domain for conformational sensing) |
| Peripheral Restricted Compounds | Glenmark (Historical), Biotech Stealth (e.g., Orion) | Osteoarthritis, Peripheral Neuropathy | Species Cross-reactivity Panel (Human/Cyno/Rat essential for preclinical translation) |
| Biologic / Peptide Modulator | Emerging Biotech & Academia | Refractory Pain, Inflammatory Itch | Cell Surface Binding Validation (Need full-length lentivirus cell lines) |
Key Genetic Variants
TRPA1 gene polymorphisms may influence drug response and disease susceptibility. According to UniProt (O75762), the following validated variants are documented:
- rs13268757 (UniProt VAR_020660)
- rs16937976 (UniProt VAR_047471)
- rs920829 (UniProt VAR_020661)
These mutations should be considered in pharmacogenomic studies and patient stratification for TRPA1-targeted therapies.